Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.3, Iss.1, 2002-01, pp. : 65-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomic considerations of the paraoxonase polymorphisms

By Furlong Clement E Cole Toby B Jarvik Gail P Costa Lucio G

Pharmacogenomics, Vol. 3, Iss. 3, 2002-05 ,pp. : 341-348

Future Medicine

Access to resources Recommend Favorite

Angiotensin II receptor blockers for the treatment of hypertension

By See Sharon

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1795-1804

Informa Healthcare

Access to resources Recommend Favorite

Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension

By Smith David H.G.

Drugs, Vol. 68, Iss. 9, 2008-01 ,pp. : 1207-1225

Adis International

Access to resources Recommend Favorite

The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension

By Thomas G. Neil

Drugs & Aging, Vol. 23, Iss. 2, 2006-01 ,pp. : 131-155

Adis International

Access to resources Recommend Favorite

Hypertension guidelines: angiotensin II receptor antagonists have a role

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 287, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite